Navigation Links
NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
Date:8/14/2010

SANTA CLARA, Calif., Aug. 12 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, today announced financial results for the second quarter ended June 30, 2010. More details on the financial results are available in the Form 10-Q, filed with the Securities and Exchange Commission.

"In the last 12 months, we have made tremendous progress in commercializing our initial solution, QTinno™," commented Vincent Renz, NewCardio's President and CEO. "Additionally, we have solidified our infrastructure to better position the Company for success, including a management transition and an expanded line of credit. Specifically, we have signed Master Services Agreements (MSAs) with three of the five largest contract research organizations (CROs), and leading, forward-thinking drug developers are increasingly interested in incorporating QTinno in their study designs. In addition, we are increasingly excited about the long-term potential for our innovative platform technology. We believe we have the potential to add value to each and every one of the electrocardiographs (ECG) performed each year. We expect our CardioBip™ to become a powerful clinical diagnostic tool in the emerging mobile healthcare space enabling a cost effective means for remotely capturing and transmitting a 12 lead ECG.  It will expand the breadth of cardiovascular disease that can be effectively monitored remotely. Our Cardio3KG™ solution has the potential to become the gold standard for timely and accurate diagnosis of acute coronary syndrome, ultimately saving lives, health care costs and litigation expenses. And these solutions are just the start.  Our platform technology promises a wide range of solutions, each targeting substantial market opportunities with unrivaled, state-of-the-art technology."

Year-to-Date Highlights
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
2. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
3. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
4. NewCardio Announces Master Services Agreement With Dedicated Phase I
5. NewCardio Leadership to Present Two Abstracts at ISCE Conference
6. Vincent W. Renz Joins NewCardio as President
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. ResMed Announces Deferred Conversions in Connection With Stock Split
9. Trubion Announces Dates for Second-Quarter and First-Half 2010 Earnings Conference Call
10. Mylan Announces Completion of Add-On Offering of Senior Notes
11. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... YORK , July 25, 2014  Smile Train ... to showcase their Virtual Surgery Simulator among leading ... which will take place in Washington, D.C. ... the Performing Arts. "Smile Train is ... alongside the talented community of innovators in health and ...
(Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
(Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
(Date:7/28/2014)... July 28, 2014 According to court documents, ... owner of The Marcal Group (TMG), met with ... (HMG). A contract, as well a broad project outline, were ... as well as branding services and marketing. , ... by HMG throughout the course of the project, praise was ...
(Date:7/28/2014)... Downers Grove, IL (PRWEB) July 28, 2014 ... marketing company for mental health professionals, announced today its ... Family Therapy (IAMFT). This new relationship allows TherapySites ... IAMFT members, adding exclusive benefits and promotional offers. , ... business is being done today. With nearly 3 ...
(Date:7/28/2014)... July 28, 2014 According to the Heartburn ... a comprehensive guide that will help people get rid of ... all the necessary information about heartburn and acid reflux. In ... about heartburn , and risk factors for reflux disease. ... help people get rid of symptoms of reflux disease naturally ...
(Date:7/28/2014)... July 28, 2014 Shore Points Capital ... its investment in Loftware, Inc., through a recapitalization of ... Points was the lead investor in Loftware for over ... become the leading international provider of enterprise level software ... been a great investment for us, and we are ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
Breaking Medicine News(10 mins):Health News:Calko Medical Center Loses Website Twice over Non-Payment, According to Court Documents 2Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
... over past 20 years due to suffocation, strangulation , ... accidental injury or death associated with crib bumper pads ... University School of Medicine in St. Louis. , Many ... protect babies from injury. But the researchers reviewed U.S. ...
... 2007 Late-breaking results from the ENDEAVOR IV trial, ... the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting ... overall safety profile (equivalent rates of death, heart attack, ... 1 year. , In addition, the Endeavor stent ...
... Lack Proper Healthcare Coverage, SAN FRANCISCO, ... Chapter of Autism Speaks today announced the ... Commission on,Autism,s recommendations to ensure appropriate and ... These recommendations were,finalized and presented to the ...
... MINNEAPOLIS, Oct. 22 Building upon its impressive ... laying out,a global vision, which will propel it ... orthopaedic research, education and new product,innovation, will solidify ... Over the next year, MORF will be ...
... than 450 people gathered on,Tuesday, October 9, at The ... 18th Annual CATCH Night of Champions. The event,featured a ... ceremony. The,event raised $225,000, with more than $38,000 raised ... been a major supporter of the charity since,1989, and ...
... has significantly increased life expectancy in early tests of ... most aggressive form of brain cancer in adults − ... Mayo Clinic in Jacksonville. , The vaccine represents a ... says neurosurgeon Kent New, M.D., Ph.D., who will be ...
Cached Medicine News:Health News:Crib Bumper Pads Too Risky for Baby 2Health News:ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 3Health News:Mayo Clinic tests novel vaccine for aggressive brain tumors 2
... The Angio-Seal vascular closure device ... following catheterization procedures, allowing for ... The device creates a mechanical ... between a bio-absorbable anchor and ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: